Trubion

Trubion

Type	Public company
Traded as	NASDAQ: TRBN
Industry	Biopharmaceutical
Fate	acquired by Emergent BioSolutions (2010)
Founded	1999
Headquarters	Seattle, WA
Products	Protein-based therapeutics
Website	www.trubion.com

Trubion was a publicly held biopharmaceutical company that was focused on creating a pipeline of protein-based therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. Trubion was acquired by Emergent BioSolutions on October 28, 2010.^[1] Trubion was established in 1999 in the State of Washington as an early stage development company, and was later reincorporated in October 2002 in the State of Delaware.

In December 2005, Trubion entered into a collaborative agreement with Wyeth^[2] for the development and worldwide commercialization of CD20-directed therapeutics. The agreement also included the development and worldwide commercialization of certain other product candidates directed to targets other than CD20. The research portion of Trubion’s contract with Wyeth extended through December 22, 2009.

Former product pipeline

Name	Platform	Indication	Status	Collaboration	Research
TRU-015	SMIP	Rheumatoid arthritis	Phase 2b	Wyeth	Phase 2b initiation^[3] EULAR data^[4]
SBI-087	SMIP	Rheumatoid arthritis	Phase 1	Wyeth	Recent data^[5]
SBI-087	SMIP	Systemic lupus erythematosus	Phase 1	Wyeth
TRU-016	SMIP	Chronic lymphocytic leukemia	Phase 1/2	Trubion Proprietary Technology	ASCO 2008 Poster Presentation^[6]
TRU-016	SMIP	Non-Hodgkin lymphoma	Pre-clinical	Trubion Proprietary Technology
TRU-016	SMIP	Autoimmune disease and inflammation	Pre-clinical	Trubion Proprietary Technology

Former technology

Trubion’s product development efforts were focused on three technology pillars: SMIP protein therapeutics, SCORPION protein therapeutics, and TRU-ADhanCe potency enhancing technology for immunopharmaceuticals.

SMIP, or small modular immunopharmaceutical, therapeutics are single chain polypeptides comprising one binding domain, one hinge domain and one effector domain designed in an effort to meet predetermined therapeutic specifications for specific diseases. SMIP therapeutics are mono-specific (they recognize and attach to single antigen targets and initiate biological activity). Trubion worked on SMIP drug candidates that targeted validated antigens with the same specificity and predictable biological activity as mAbs.

SCORPION protein therapeutics are also single chain polypeptides composed of functional domains from naturally occurring proteins. The difference between SMIP and SCORPION technologies is that SCORPION compounds are multi-specific therapeutics that are capable of targeting two or more antigens simultaneously.

TRU-ADhanCe potency enhancing technology was designed to enhance the potency of existing therapies that work through Fc-directed or antibody-directed cellular cytotoxicity, or ADCC. TRU-ADhanCe technology could be applied late in development to established manufacturing lines and generate candidates with increased ADCC and longer in vivo half lives.

References

Pharmaceutical companies of the United States

Abbott Laboratories Acorda Therapeutics Actavis Aderis Pharmaceuticals Adolor Corporation Alcon Alexion Pharmaceuticals Alkermes Allergan Alza Amgen Amylin Pharmaceuticals ARIAD Pharmaceuticals ARYx Therapeutics Avax Technologies Baxter International BioCryst Pharmaceuticals Biogen Idec Biolex Biovest Biovista Bradley Pharmaceuticals Bristol-Myers Squibb CancerVax Century Pharmaceuticals Cephalon Ceragenix Pharmaceuticals Combe Incorporated Cortex Pharmaceuticals CoTherix Covance Covidien Cubist Pharmaceuticals Cutter Laboratories CytoSport CytRx Danco Laboratories DNAPrint Genomics Epix Pharmaceuticals Eli Lilly and Company Elorac Endo Pharmaceuticals Ethicon Endo-Surgery Ethicon Inc. Forest Laboratories Galena Biopharma GenVec Genentech Genta Gilead Sciences Hospira ImClone Systems Institute for OneWorld Health Intercept Pharmaceuticals ISTA Pharmaceuticals Ivax Corporation Janssen Biotech Johnson & Johnson Kinetic Concepts King Pharmaceuticals Kinray KV Pharmaceutical Leiner Health Products Mallinckrodt Martek Biosciences Corporation S. E. Massengill Company McKesson Corporation McNeil Laboratories Melior Discovery Mentholatum Merck & Co. Miles Laboratories Mylan Myriad Genetics Naurex Nereus Pharmaceuticals Northwest Biotherapeutics Norwich Pharma Services NovaBay Pharmaceuticals Nuvelo Organon International Ortho Pharmaceutical Ortho-McNeil Pharmaceutical OSI Pharmaceuticals Ovation Pharmaceuticals Par Pharmaceutical Parke-Davis Perrigo Pfizer Pharmaceutical Product Development Prasco Laboratories Procter & Gamble Proteon Therapeutics Purdue Pharma Qualitest Quark Pharmaceuticals Regeneron Repros Therapeutics Respa Pharmaceuticals Rib-X Pharmaceuticals Sarepta Therapeutics Savage Laboratories Schering-Plough G. D. Searle & Company Sheffield Pharmaceuticals Smith, Kline & French Spectrum Pharmaceuticals Sterling Drug Tanox TAP Pharmaceutical Products Tec Laboratories Teva Pharmaceutical Industries Tiens Biotech Group Titan Pharmaceuticals Trevena Inc Trubion Upjohn Upsher-Smith Laboratories Valeant Pharmaceuticals Ventria Bioscience Vertex Pharmaceuticals Verus Pharmaceuticals Vion Pharmaceuticals, Inc. ViroPharma West Pharmaceutical Services Wyeth Zonite Products Corporation

List of pharmaceutical companies

This article is issued from Wikipedia - version of the Friday, October 09, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.